Surveillance and Care of the Gynecologic Cancer Survivor

Stephanie S Faubion, Kathy L MacLaughlin, Margaret E Long, Sandhya Pruthi, Petra M Casey, Stephanie S Faubion, Kathy L MacLaughlin, Margaret E Long, Sandhya Pruthi, Petra M Casey

Abstract

Background: Care of the gynecologic cancer survivor extends beyond cancer treatment to encompass promotion of sexual, cardiovascular, bone, and brain health; management of fertility, contraception, and vasomotor symptoms; and genetic counseling.

Methods: This is a narrative review of the data and guidelines regarding care and surveillance of the gynecologic cancer survivor. We searched databases including PubMed, Cochrane, and Scopus using the search terms gynecologic cancer, cancer surveillance, and cancer survivor and reached a consensus for articles chosen for inclusion in the review based on availability in the English language and publication since 2001, as well as key older articles, consensus statements, and practice guidelines from professional societies. However, we did not undertake an extensive systematic search of the literature to identify all potentially relevant studies, nor did we utilize statistical methods to summarize data. We offer clinical recommendations for the management of gynecologic cancer survivors based on review of evidence and our collective clinical experience.

Results: Key messages include the limitations of laboratory studies, including CA-125, and imaging in the setting of gynecologic cancer surveillance, hormonal and non-hormonal management of treatment-related vasomotor symptoms and genitourinary syndrome of menopause, as well as recommendations for general health screening, fertility preservation, and contraception.

Conclusions: A holistic approach to care extending beyond cancer treatment alone benefits gynecologic cancer survivors. In addition to surveillance for cancer recurrence and late treatment side effects, survivors benefit from guidance on hormonal, contraceptive, and fertility management and promotion of cardiovascular, bone, brain, and sexual health.

Figures

FIG. 1.
FIG. 1.
Society of Gynecologic Oncologists surveillance checklist. Reprinted from the American Journal of Obstetrics and Gynecology, Vol. 204, Issue 6; Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA; Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations; pages 466–478, 2011; with permission from Elsevier.

References

    1. American Cancer Society. Cancer Facts and Figures 2015. Atlanta: American Cancer Society; 2015
    1. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI). SEER cancer statistics factsheets: Cervix uteri cancer. Available at: Accessed September29, 2014
    1. SEER, NCI. SEER cancer statistics factsheets: Endometrial cancer. Available at: Accessed September29, 2014
    1. SEER, NCI. SEER cancer statistics factsheets: Ovary cancer. Available at: Accessed September29, 2014
    1. SEER, NCI. SEER cancer statistics factsheets: Vulvar cancer. Available at: Accessed September29, 2014
    1. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987;257:796–800
    1. Isin Dogan Ekici A, Kucukali T, Coskun Salman M, Ayhan A. Triple simultaneous primary gynecological malignancies in a 56-year-old patient. Int J Gynecol Cancer 2006;16:1947–1950
    1. Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013;62:44–58
    1. Leyden WA, Manos MM, Geiger AM, et al. . Cervical cancer in women with comprehensive health care access: Attributable factors in the screening process. J Natl Cancer Inst 2005;97:675–683
    1. . About Cancer Survivorship. Available at: Accessed February10, 2015
    1. Salani R, Backes FJ, Fung MF, et al. . Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–478
    1. Lalwani N, Dubinsky T, Javitt MC, et al. . ACR Appropriateness Criteria(R) pretreatment evaluation and follow-up of endometrial cancer. Ultrasound Q 2014;30:21–28
    1. Sartori E, Pasinetti B, Chiudinelli F, et al. . Surveillance procedures for patients treated for endometrial cancer: A review of the literature. Int J Gynecol Cancer 2010;20:985–992
    1. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev 2011:CD006119.
    1. Piovano E, Attamante L, Macchi C, et al. . The role of HE4 in ovarian cancer follow-up: A review. Int J Gynecol Cancer 2014;24:1359–1365
    1. Lanceley A, Fiander A, McCormack M, Bryant A. Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013;11:CD008767.
    1. Elit L, Fyles AW, Oliver TK, Devries-Aboud MC, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer. Curr Oncol 2010;17:65–69
    1. American College of Obstetricians and Gynecologists. ACOG committee opinion No. 509: Management of vulvar intraepithelial neoplasia. Obstet Gynecol 2011;118:1192–1194
    1. Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. . Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005;97:828–833
    1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual Life Outcomes 2005;3:47.
    1. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190–197
    1. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–461
    1. Weiderpass E, Adami HO, Baron JA, et al. . Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–1137
    1. Lacey JV, Jr., Leitzmann MF, Chang SC, et al. . Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 2007;109:1303–1311
    1. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245–251
    1. Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol 2012;32:321–325
    1. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–1200
    1. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330
    1. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–191
    1. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: A matched control study. Obstet Gynecol 2001;97:555–560
    1. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805–808
    1. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587–592
    1. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: A meta-analysis. Eur J Cancer 2014;50:1628–1637
    1. Guidozzi F. Estrogen therapy in gynecological cancer survivors. Climacteric 2013;16:611–617
    1. Eeles RA, Tan S, Wiltshaw E, et al. . Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259–262
    1. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:1013–1018
    1. Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000;21:192–196
    1. Mascarenhas C, Lambe M, Bellocco R, et al. . Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006;119:2907–2915
    1. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: The effect on survival. Menopause 2001;8:70–75
    1. Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93
    1. Sluijmer AV, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995;80:2163–2167
    1. Madalinska JB, van Beurden M, Bleiker EM, et al. . The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576–3582
    1. Faubion SS, Sood R, Thielen JM, Shuster LT. Caffeine and menopausal symptoms: What is the association? Menopause 2015;22:155–158
    1. Sood R, Sood A, Wolf SL, et al. . Paced breathing compared with usual breathing for hot flashes. Menopause 2013;20:179–184
    1. Stojanovska L, Apostolopoulos V, Polman R, Borkoles E. To exercise, or, not to exercise, during menopause and beyond. Maturitas 2014;77:318–323
    1. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;9:CD007244.
    1. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013;12:CD001395.
    1. Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS. Effects of acupuncture on menopause-related symptoms and quality of life in women on natural menopause: A meta-analysis of randomized controlled trials. Menopause 2014;22:234–244
    1. Dodin S, Blanchet C, Marc I, et al. . Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013;7:CD007410.
    1. Shams T, Firwana B, Habib F, et al. . SSRIs for hot flashes: A systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–213
    1. Simon JA, Portman DJ, Kaunitz AM, et al. . Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: Two randomized controlled trials. Menopause 2013;20:1027–1035
    1. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: A randomized controlled trial. Menopause 2008;15:310–318
    1. Cohen JV, Chiel L, Boghossian L, et al. . Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 2012;11:69–75
    1. Hillner BE, Ingle JN, Chlebowski RT, et al. . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057
    1. Reid DM, Doughty J, Eastell R, et al. . Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34:S3–S18
    1. Parker WH, Broder MS, Chang E, et al. . Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009;113:1027–1037
    1. Rivera CM, Grossardt BR, Rhodes DJ, et al. . Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15–23
    1. Gierach GL, Pfeiffer RM, Patel DA, et al. . Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause 2014;21:592–601
    1. Rocca WA, Bower JH, Maraganore DM, et al. . Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074–1083
    1. Rocca WA, Bower JH, Maraganore DM, et al. . Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200–209
    1. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: A 2014 update. Mol Cell Endocrinol 2014;389:7–12
    1. Lee SJ, Schover LR, Partridge AH, et al. . American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931
    1. Jensen JR, Morbeck DE, Coddington CC., 3rd. Fertility preservation. Mayo Clin Proc 2011;86:45–49
    1. Pavone ME, Hirshfeld-Cytron J, Lawson AK, Smith K, Kazer R, Klock S. Fertility preservation outcomes may differ by cancer diagnosis. J Hum Reprod Sci 2014;7:111–118
    1. Gamzatova Z, Komlichenko E, Kostareva A, et al. . Autotransplantation of cryopreserved ovarian tissue - effective method of fertility preservation in cancer patients. Gynecol Endocrinol 2014;30 Suppl 1:43–47
    1. Di Cosimo S, Alimonti A, Ferretti G, et al. . Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004;15:1065–1071
    1. Centers for Disease Control and Prevention (CDC). The United States medical eligibility criteria for contraceptive use, 2010. MMWR 2010;59(RR-4):1–85. Available at: Accessed September28, 2014
    1. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: A long-term comparative cohort study. Hum Reprod 2013;28:2966–2971
    1. Kudesia R, Singer T, Caputo TA, et al. . Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol 2014;210:255.e1–4
    1. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecol Oncol 2012;125:477–482
    1. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–3853
    1. Incrocci L, Jensen PT. Pelvic radiotherapy and sexual function in men and women. J Sex Med 2013;10(Suppl 1):53–64
    1. Krychman ML, Carter J, Aghajanian CA, Dizon DS, Castiel M. Chemotherapy-induced dyspareunia: A case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. Gynecol Oncol 2004;93:561–563
    1. Wiggins DL, Wood R, Granai CO, Dizon DS. Sex, intimacy, and the gynecologic oncologists: Survey results of the New England Association of Gynecologic Oncologists (NEAGO). J Psychosoc Oncol 2007;25:61–70
    1. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013;100:916–921
    1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902, quiz 903–884
    1. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957–966
    1. Christinat A, Pagani O. Practical aspects of genetic counseling in breast cancer: Lights and shadows. Breast 2013;22:375–382

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다